Synairgen announces results of in vitro studies showing antiviral activity of interferon-beta against key SARS-CoV-2 variants
Synairgen plc (SNG.L) Results of in vitro studies
Share Talk Weekly Stock Market News, Sunday 16th May 2021
Huge honour to support Ride4Rahma Challenging 70-mile ride from Dewsbury to the historic city of York to raise funds for ongoing projects in the Balkans registration charity, please donating here & share
Synairgen plc (SNG.L) Full Year Results/Significant progress continues towards a treatment for COVID-19
Preliminary results for the year ended 31 December 2020
Weekend Edition, Bulletin Board Heroes, Sunday 2nd May 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Zak’s Sunday Roast, 2nd May, analysis of stocks, markets by traders and investors.
Grab a coffee, settle down and listen to the guy’s view – thoughts covering this week in the markets. New and exclusive to Share Talk.
Share Talk Weekly Stock Market News, Sunday 2nd May 2021
People making exaggerated claims about a company or its prospects is something which we are all familiar with regarding the stock market. But of course, if “ramping” worked, every stock
Synairgen plc (SNG.L) Home Cohort data of SG016 Phase II trial
Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial
Zak’s Sunday Roast, 18th April, analysis of stocks, markets by traders and investors.
Grab a coffee, settle down and listen to the guy’s view – thoughts covering this week in the markets. New and exclusive to Share Talk.
Weekend Edition, Bulletin Board Heroes, Sunday 18th April 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Weekend Edition, Bulletin Board Heroes, Sunday 28th February 2021
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Synairgen plc (SNG.L) Inclusion in US ACTIV-2 trial
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
